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Abstract
 In short, analysis of spiked urine samples by immunoassay and HPLC-MS-MS 
revealed that there is no significant difference in the recoveries obtained, however, a 
tendency for higher values obtained through immunoassay analysis was observed.  HPLC-
MS-MS offers good precision and analysis, given that enough time is spent to optimize the 
instrument conditions to its full potential and especially when including internal standards.  
Deuterated standards have shown to be a valuable tool for this purpose.  Enzyme 
immunoassay methods do not require sophisticated instrumentation, but the precision can 
not be improved beyond its existing parameters. Liquid and solid phase extractions are a 
necessity for the HPLC-MS-MS analysis, while unpurified urine samples seem to yield good 
recoveries by immunoassay.  Urine, as a matrix, seemingly can influence results in both ways.  
Urine may create higher recoveries in immunoassay methods due to cross-reactivity, while 
precipitation and entrapment of the analyte seems a more predominant factor for HPLC-MS-
MS assays.  Ultimately, the decision between using HPLC-MS-MS and immunoassay would 
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Introduction 
 Coronary heart disease is the leading cause of death in many western countries such 
as the United States of America. The research for early indicators of risk factors associated 
with this disease is therefore of increasing interest.  One possible cause under investigation is 
oxidative damage caused by free-radical damage.  This radical oxidative damage has been 
associated with various health conditions such as atherosclerosis (Meagher and Rader, 2001), 
ischaemia, inflammation (Cracowski et al., 2002), Alzheimer’s Disease, and Parkinson’s 
Disease (Pratico et al., 2001).  Formation of free radicals in vivo may result in damage to 
DNA, proteins, and lipids.  Accurate identification and analysis of markers of oxidative 
damage can provide insight into the mechanism(s) of action for development and 
progression of these diseases.    
 Free-radical non-enzymatic oxidation of arachidonic acid (20:4), especially in situ on 
phospholipids bilayers, can lead to the production of 4 sets of 16 regioisomeric compounds 
each, termed F2-isoprostanes (Pratico, 1999).  One class of isoprostanes (see Fig. 1), 
consisting of 16 isomers referred to as Class III F2-Isoprostanes, has been suggested to be an 
excellent biomarker of in vivo oxidative stress (i.e. levels of F2-isoprostanes in human tissue, 
plasma, and urine are highly correlated with the amount of oxidative stress occurring in vivo). 
In addition, F2-isoprostanes retrieved from biological samples remain stable when stored at –
80ºC (Morrow & Roberts, 1997).  Of the F2-isoprostane isomers, 8-iso-PGF2α has been 
found to have one of the highest concentrations in urine and plasma and is detectable when 
extracted from biological systems (Cracowski et al., 2002).  These isoprostanes occur both 
esterified to plasma proteins and free in plasma but only in the free form in urine.  8-iso-
PGF2α levels have been analyzed in human studies using either gas chromatography/mass 
spectroscopy (GC/MS) or immuno-assay techniques (ELISA=enzyme linked immunoassay), 
revealing elevated levels in urine samples of cigarette smokers, diabetic patients, and patients 
with acute myocardial infarction (Pratico et al., 2001). 
 
Fig 1:  Chemical Structure of 8-iso-PGF2α (15-F2t-isoprostane, top left) with some Isomers 
 
 Interestingly, 8-iso-PGF2α has also been shown to possess potent vasoconstrictive 
properties in rats (Morrow et al., 1990) and increased levels in patients were found after 
acute coronary angioplasty (Reilly et al., 1997).  Higher levels of urinary 8-iso-PGF2α found in 
patients with coronary heart disease, along with C-receptor protein, indicate that this 
compound can be used as a reliable indicator for this condition (Schwedhelm et al., 2004).  
In one study, urinary levels were 129 +/- 17 pg/mL in normal healthy patients, while levels 
were 342 +/- 5 pg/mL in patients under physical stress (McKinney et al., 2000). 
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 In addition to GC/MS and ELISA techniques, quantification of isoprostanes using 
HPLC-MS techniques has garnered interest as a useful method of oxidative stress 
measurement.  Detection of the F2 isoprostane isomers has been investigated using HPLC 
coupled to electrospray ionization Mass spectrometry since the beginning of isoprostane 
research (Waugh and Murphy, 1996).  Advances in mass spectrometry, especially in the 
interface designs (e.g. atmospheric pressure ionization) and tandem MS (e.g. triple 
quadrupoles), have allowed for sensitivity and precision comparable to GC-MS methods 
(Lawson & FitzGerald, 2002).  Mass spectrometry offers great selectivity and sensitivity, but 
does require long workup procedures and a heavy investment in capital (Morrow, 2005).  
While GC-MS-MS requires an additional esterification process to detect isoprostanes, LC –
MS-MS methods do not, significantly reducing the workup time required per sample.  
 Enzyme Immunoassays theoretically allow for very rapid analysis of blood or urine 
samples.  However, high levels of workup are usually assumed to be required to reduce 
cross-reactivities and increase precision.  A current study comparing an EIA method to 
GC/MS has shown a greater than 30-fold increase in detected 8-iso-PGF2α levels by 
immunoassay, with essentially no correlation to results found using GC/MS (Il’yasova et al., 
2004).  Immunoassay methods, while showing discrimination against most isomers, may not 
have safeguards against cross-reactivities with certain isomers or metabolites (Lawson & 
FitzGerald, 2002).  Studies have suggested that cross-reactivities are only 1% in recent EIA 
kits, leading researchers to speculate on structurally unrelated compounds showing cross-
reactivity (Schwedhelm & Boger, 2003).  Immunoassay techniques are easily approachable 
for research groups familiar with them and offer a lower cost, albeit less accurate, alternative. 
A recent review concluded that more studies are required comparing immunoassay methods 
to mass spectrometry in determining isoprostane levels (Morrow, 2005) 
Over the period of this project, urine samples were analyzed by EIA and HPLC-MS-
MS using varying purification methods to explore the benefits and disadvantages of both 




 The main goal of this project was to compare accuracy, precision, and amount of 
sample preparation needed for assays analyzing levels of F2 alpha isoprostane in urine using 
both enzyme immunoassay and HPLC-MS-MS. To achieve this goal, different purification 
procedures were tested for necessity and efficiency by obtaining recoveries through each 
method.  In addition, the sensitivity of each method was determined.  Different 
chromatographic conditions were verified to optimize results with HPLC-MS-MS.   
 
 
Material and methods 
Experimental Procedures  
In short, the Experimental Procedures Performed were: To… 
1. Determine the recovery of urinary 8-iso-PGF2α using HPLC-MS/MS based on spiked 
urine samples. 
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2. Determine the recovery of urinary 8-iso-PGF2α using Enzyme Immunoassay based on 
spiked urine samples. 
3. Determine the recovery of urinary 8-iso-PGF2α based on spiked water samples using 
both Enzyme Immunoassay and HPLC-MS-MS. 
4. Correlate recoveries against purification levels achieved through differing extraction 
methods and the associated matrix-effect. 
5. Compare the recoveries of urinary 8-iso-PGF2α between HPLC-MS/MS and Enzyme 
Immunoassay methods in terms of accuracy and reproducibility. 
An overall visual representation of methods used is given in Figure II, below. 
Samples and Standard 
 For all experiments, several urine spot samples from the same subject were pooled and 
stored at -20oC for several weeks.  8-iso-PGF2α Standard was obtained from Cayman (Ann 
Arbor, MI). All chemicals used for this analysis were of analytical grade or superior and were 
obtained from Sigma Aldrich (St. Louis, MO).  Workup procedures were optimized starting 
from previous reported methods (Liang et al., 2003).  Most samples were spiked individually 
with 8-iso-PGF2α standard (66.7 ng) directly before the purification procedures used (see 
Table II). 
Purification of 8-iso-PGF2α from Urine 
Urine samples (2.5 mL) were centrifuged (DAMON, IEC HN-SII, 400 g) at 2800 rpm 
for 10 minutes to remove sediments.  Supernatant portions were then extracted with ethyl 
acetate (2 x 3 mL) and dried under a stream of nitrogen.  An aliquot of those samples was then 
reconstituted in 5% ethanol at pH 3 (2 x 1 mL) and purified by Solid Phase Extraction 
(Supelco Envi-Chrom P, 6mL; Bellefonte, PA).  Some of the samples were processed without 
purification, some with only liquid phase extraction, and some with full purification (See 
Table II). 
Solid Phase Extraction 
 Columns were preconditioned with methanol (3 mL) followed by 1 mM HCl (3 mL).  
Samples were loaded onto the columns and drained to the adsorbent phase by a slight 
vacuum.  1mM HCl (3 mL) followed by hexane (2.5 mL) were used for washing.  Ethyl 
acetate containing 1% methanol (4.5 mL) was used as the eluent.  This ethyl acetate fraction 










Fig 2:  Visual Representation of General Purification and Analytical Methods 
 
 
HPLC-MS-MS Analysis of 8-iso-PGF2α
 Dried samples were reconstituted in acetonitrile (600 uL) and filtered through 0.2 um 
nylon syringe filters (Waters, Milford, MA).  HPLC separation was achieved by a Waters 2695 
HPLC, using a Xterra MS C18 column (Waters, 2.5 um, 3.0x20 mm, IS).  15 uL of each sample 
was injected into a gradient mobile phase, described below in Table I.  Column conditions 
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were as follows:  0.700 mL/min flow rate, 20oC column temperature, and 15 minute total 
sample run time.  Detection of the 8-iso-PGF2α was performed by a Quattro Ultima Triple 
Quadrupole Mass Spectrometer (Micromass Ltd., Manchester, UK) using negative ion mode.  
Selective Reaction Monitoring (SRM) was used for selecting the deprotonated molecular ion 
(353.5 m/z), allowing observance of the daughter ion of highest abundance (193 m/z), as 
reported in previous experiments (Liang et al., 2003).   
Table I:  Gradient Eluent Method for HPLC-MS-MS Analysis of Samples 
  0 - 7 minutes 7 - 9 minutes 9 - 15 minutes 
0.1% Acetic Acid 80% 35% 80% 
Acetonitrile 20% 65% 20% 
Enzyme Immunoassay (EIA) Analysis of 8-iso-PGF2α
 Dried samples (Groups A, B, and D in Table II) were reconstituted in ethyl acetate 
and diluted 1:300. These were then dried under nitrogen, and reconstituted in EIA buffer 
(Cayman).  Fresh urine samples (Group C in Table II) used in this test were only given a 1:145 
dilution with EIA buffer (Cayman).   Enzyme Immunoassay was performed following 
instructions by the manufacturer (8-Isoprostane EIA Kit, Cayman).  Specifically, standards, 
blanks, and samples were injected into individual wells coated with Anti-Rabbit IgG.  
Antiserum is injected to allow binding of the isoprostanes, along with an 8-iso-PGF2α –
acetylcholinesterase conjugate tracer.  Added Ellman’s reagent is chemically altered by the 
acetylcholinesterase, producing a yellow pigmentation.  Absorbance readings were read at 
405 nm and 414 nm on an automated plate reader, and the wavelength yielding maximum 
difference between maximum binding – of antiserum – wells and blanks was used for 
quantification of isoprostanes.  Isoprostane concentrations were determined through external 
calibration curves. 
Comparison of HPLC-MS-MS and EIA Techniques for Determination of Urinary 8-iso-PGF2α 
among Different Purification Levels and Matrices.  
Pooled urine spot samples were used to assess accuracy and precision of HPLC-MS-
MS and EIA techniques in relation to the number of purification steps.  Samples were 
prepared identically and simultaneously using the techniques described above and were then 
divided for testing using HPLC-MS-MS and EIA.  Further subdivision among these samples 
was done as follows – performed on both sets of samples:  One group of samples was given 
both liquid extraction and solid phase extraction before analysis (Group A, Table II), another 
group was given only liquid phase extraction (Group B, Table II), while yet another was not 
given any purification at all (Group C, Table II).  Samples without purification were only 
analyzed by EIA due to the possibility of damage and contamination to the HPLC-MS 
instrumentation.  See Table II below for a complete breakdown of samples. 
Another sample of pooled urine was split into 12 sample allotments.  HPLC grade 
water was also split into 12 sample allotments to test for matrix differences between urine 
(Group E, Table II) and water (Group F, Table II). All urine and water samples were spiked 
with 667 ng/mL 8-iso-PGF2α Standard (0.100 mL).  Liquid and solid phase extraction 
procedures were performed on all samples.  Urine and water samples, six each, were analyzed 
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using the EIA analysis procedure listed above.  Remaining urine and water samples were 
analyzed by HPLC-MS-MS by the procedure listed above.   
Table II:  Sample Design for Analysis of Purification Effects on Accuracy and Precision Using 
HPLC-MS-MS and EIA 
Sample Group Nx Matrix Spike* Work-Up Procedure Analysis Performed** 
A 2x5 Urine 66.7 ng Liquid & Solid Phase Extraction HPLC & EIA 
B 2x6 Urine 66.7 ng Liquid Phase Extraction HPLC & EIA 
C 1x6 Urine 66.7 ng None EIA only 
D 2x6 Urine 0 ng Liquid & Solid Phase Extraction HPLC & EIA 
E 2x6 Urine 66.7 ng Liquid & Solid Phase Extraction HPLC & EIA 
F 2x6 Water 66.7 ng Liquid & Solid Phase Extraction HPLC & EIA 
x:  N = Number of sample preparations  
* Spike:  Amount of 8-iso-PGF2α standard added for recovery purposes 
** HPLC:  High Pressure Liquid Chromatography w/ Mass Spectrometry 
 EIA:  Enzyme Immunoassay 
Analysis of D4-8-iso-PGF2α Recovery in Urine Matrix Using HPLC-MS-MS 
 Six urine samples were spiked with D4-8-iso-PGF2α (Cayman) and processed by liquid 
and solid phase extractions to test for absolute recovery of 8-iso-PGF2α compound using the 
described methods.  Analysis performed by HPLC-MS-MS was followed as above, selecting 
the ion transition 357m/z to 197m/z instead of 353m/z and 193m/z.  Recoveries found for the 
deuterated standard can be used to determine the true losses in recovery expected after each 
processing method and analytical technique.  Analysis was not performed by EIA. 
Statistical Treatment of Data 
 Data obtained by HPLC-MS-MS and EIA were transferred to data sheets (Microsoft 
Excel 2002, v. 10.2614.2625).  Standard curves and linear regression analysis of those curves 
were used to determine the concentrations of eluted samples.  Statistical analyses were 
performed by SPSS 13.0 (SPSS Inc., Chicago, IL).  Data values were reported as mean +/- 
standard deviation, and t-test p-values were considered significant if less than or equal to 
0.05.  Detection and quantification limits for the HPLC-MS-MS method were found by 
making 6 injections of very dilute standard dilutions (13 ng/mL).  The standard deviation was 
multiplied by 3 to obtain the detection limit and multiplied by 6 for the quantification limit 
(Berthouex, 1994).   
 All data obtained through HPLC-MS-MS and EIA assays were compared using a 
linear mixed model.  This model kept an overall p-value of 0.05, avoiding multiple 
comparisons.  Fixed factors were amount of purification (full, half, or none), amount of spike 
(whether deuterated or normal isoprostane standard), type of analysis (MS vs. EIA) and 
matrix used (urine vs. water).  The observed parameter was the % recovery, while the day of 
analysis was a random parameter.  A Bonferroni post hoc test was used afterward to test for 





 Quantification and Recovery by HPLC-MS-MS.  Urine samples were treated with an 
8-iso-PGF2α spike (66.7 ng).  Untreated urine samples were quantified by HPLC-MS-MS to 
determine baseline concentration, which was found to be 1.841 +/- 0.569 ng/mL (Table III). 
Urine samples purified by liquid and solid phase extractions possessed an average recovery of 
77.95 +/- 7.67%, while those purified only by liquid phase extraction had an average recovery 
of 54.01 +/- 19.97% (Table III).  Statistical analysis, performed using an unpaired two-tailed 
Student T-test, did not show a significant difference between values associated with full 
purification or partial purification (P=0.104) for the HPLC-MS-MS comparison.  A standard 
curve found for one of the HPLC-MS-MS runs is given below in Fig IV. 
 
Fig III:  Standard Curve for EIA Analysis



































Fig IV:  Standard Curve for MS Analysis of 8-iso-
F2a






















Table III:  Recoveries of Urine and Water Samples Spiked with 8-iso-PGF2α Using 
Different Purification Procedures and Analyzed by Both EIA and HPLC-MS-MS
     Mean Recoveries 
Sample 
Group N Matrix Spike* Purification** HPLC-MS-MS EIA 
A 10 Urine 66.7 ng Full 77.95 +/- 7.67 96.02 +/- 17.1 
B 12 Urine 66.7 ng Half 54.01 +/- 19.97 43.32 +/- 26.8 
C 6 Urine 66.7 ng None N/A 98.98 +/- 7.2 
D 12 Urine 0 ng Full 1.841 +/- 0.569A  0.651 +/- 0.105A 
E 12 Urine 66.7 ng Full 22.22 +/- 1.42 70.29 +/- 5.3 
F 12 Water 66.7 ng Full 77.02 +/- 10.53 53.56 +/- 3.9 
* Spike:  Amount of 8-iso-PGF2α standard added for recovery purposes 
** Full:  Both Liquid and Solid Phase Extraction Performed;  Half:  Only Liquid Phase Extraction Performed;  None:  No 
purification was performed before analysis 
A These samples were not spiked – these values are the baseline 8-iso-PGF2α levels detected, given in ng/mL   
 































Data points represent mean +/- standard deviation for select sample groupings.  Full purification = liquid and solid phase 
extraction during purification.  Half Purification = only liquid phase extraction during purification.  Water matrix samples = 
water was used in lieu of urine for the matrix, followed by full purification and analysis.  X-axis represents the recovery 
obtained through Immunoassay analysis, while the Y-axis represents the recovery obtained through HPLC-MS-MS 
analysis.  Error bars not including the diagonal line may indicate significantly different recoveries between the two 
techniques. 
 
Detection limits by HPLC-MS-MS.  Detection limits were determined using a 13 ng/mL 
standard and quantifying this by HPLC-MS-MS.  By the 8-iso-PGF2α method used in this 
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laboratory, the detection limit was 8.813 ng/mL, and the quantification limit was 17.626 
ng/mL.   
 
Recovery of D4-8-iso-PGF2α by HPLC-MS-MS.  Peak areas obtained by HPLC-MS-MS 
analysis of urine samples spiked with D4-8-iso-PGF2α indicated an average recovery of 86.02 
+/- 5.69%.  When compared to the 8-iso-PGF2α standards, there was no significant difference 
in recovery (P<0.001, see Table III for 8-iso-PGF2α standard data). 
 
Quantification and Recovery by Enzyme Immunoassay.  Most urine samples were spiked 
with 8-iso-PGF2α (66.7 ng).  Untreated Urine samples were quantified by the EIA method 
described by the manufacturer (8-isoprostane EIA kit, Cayman Chemical) to have a baseline 
concentration of 0.651 +/- 0.105 ng/mL (Table III).  Unpurified samples possessed a recovery 
of 98.98 +/- 7.2%; urine purified with liquid phase extraction, 43.32 +/- 26.8%; urine purified 
with liquid phase and solid phase extractions, 96.02 +/- 17.1% (Table III).  A standard curve 
found for one of the plate developments is found in Fig. III, above. 
 
Matrix Effect Analysis by EIA and HPLC-MS-MS.  Urine samples spiked with standard gave 
EIA recoveries of 70.29 +/- 5.27% at 414 nm and HPLC-MS-MS recoveries of 22.22 +/- 1.42%.  
Water samples spiked with standard gave EIA recoveries of 53.56 +/- 3.85% at 414 nm and 
HPLC-MS-MS recoveries of 77.02 +/- 10.53%.  Recoveries among both methods are found in 
Table III, above.   
 
Overall Statistical Comparison of Data.  Data subjected to the linear mixed model suggested 
significant effects in the extent of purification performed and the matrix utilized.  However, 
no significant effect was discovered for the type of analysis (HPLC-MS-MS vs. EIA, P=0.602) 
or the type of spike used (D4-8-iso-PGF2α vs. 8-iso-PGF2α , P=0.254).  The Bonferroni post hoc 
test comparison revealed that half-processed samples (samples without solid phase extraction) 
had significantly lower recoveries when compared to fully processed or unprocessed samples 
(P<0.001).  Fully processed and unprocessed samples were not significantly different 
(P=0.643).  
Discussion 
Exploration of HPLC-MS-MS and Enzyme Immunoassay methods for urinary 8-iso-PGF2α 
analysis can lead to powerful tools in oxidative stress research.   Ease of use, precision, 
accuracy, and the amount of required labor are all important factors when analyzing this 
marker.  Overall, recoveries from the urine samples obtained in this procedure were 
acceptable.  Purification by solid phase extraction appeared to be a valuable procedure.  
HPLC-MS-MS appears to possess more versatility in the number of related compounds it is 
able to analyze and can be optimized for greater reproducibility by including internal 
standards.  Enzyme Immunoassay methods give adequate results quickly and with little 
calibration, but recoveries obtained were often greater than 100%.  These observations will be 
explained in more detail below.  Statistically, there was no significant difference found 
between the HPLC-MS-MS and Immunoassay techniques in the overall comparison.   
 10
 HPLC-MS-MS analysis of the urine samples yielded desirably consistent results for 
samples with full purification.  Among the samples run by HPLC-MS-MS, standard deviation 
of recovery tends to increase for those not utilizing solid phase extraction.  Samples processed 
with solid phase extraction (SPE) were recovered at 77.95 +/- 7.67%, while those without SPE 
were recovered at only 54.01 +/- 19.97%.  Even though there was not a significant difference 
among the values obtained (P=0.104) these inconsistencies should be sufficient to suggest that 
SPE provided a much more competent analysis.  However, spikes used in this procedure were 
at higher concentrations than levels typically found in human urine, which implies that these 
differences might be even more crucial at normal 8-iso-PGF2α concentrations.  
 EIA analysis of the urine samples gave desirable results with a slightly larger variance 
compared to HPLC-MS-MS.  Urine samples with full purification had a mean recovery of 
96.02 +/- 17.1%.  Interestingly, urine without purification had a mean recovery of 98.98 +/- 
7.2%, giving both the value closest to 100% and with the lowest standard deviation among all 
samples.  Samples with only liquid phase extraction had significantly lower recoveries 
compared to samples with the full purification (P=0.004).  This result was unexpected, as less 
purified samples were expected to have higher recoveries due to smaller losses during sample 
processing and due to the higher chance of cross-reactivities.  Both HPLC-MS-MS and 
immunoassay methods experienced losses in recovery for samples processed with only liquid 
extraction.  As explained in full below, it was postulated that precipitations formed following 
drying procedures and subsequent frozen storage may have trapped the analyte, making it 
unavailable for the assay.    
 As stated above, the best recovery and lowest deviation within results was obtained 
through enzyme immunoassay analysis without any urine purification, followed by HPLC-
MS-MS and enzyme immunoassay with full purification.  To assume, however, that enzyme 
immunoassay techniques are superior is not directly evident.  These results could be 
misleading due to cross-reactivities and procedural errors during the injection of samples into 
the plate wells and wash steps during the Immunoassay.  Preventing cross-contamination of 
injected wells during the development and wash steps requires caution and experience.  Also, 
it has been postulated that biological components within urine may interfere with the 
binding of 8-iso-PGF2α to antibodies residing on EIA plate wells.  Similarly, biological 
components may actually bind to the antibodies themselves.  This assertion was justified by 
the presence of recoveries that were as high as 107% for the EIA method, which was not 
observed for the HPLC-MS-MS method, even though both sample sets were processed in 
parallel.  Furthermore, the slightly higher recoveries found in the unpurified urine sample at 
least indicate that there were no inhibitive effects of extra urine components on the analysis.  
 Difficulties with the EIA method were various.  As noted, the procedure for the urine 
purification was nearly identical to that for the HPLC-MS-MS.  Time associated with plate 
development and the number of pipetting procedures reduces the advantages of enzyme 
immunoassay as a quantification method.  Possible benefits of this method are the low cost 
and the ability to process numerous samples in series – but this benefit is marred by the high 
amount of time and complexity of setup required to process, wash, and develop the plates.  In 
the first assay attempted for this experiment, plate readings did not develop consistently, 
indicating potential deviation between kits.  Also, Immunoassay kits can generally analyze 
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only one compound per assay, as they do not possess the ability to quantify closely related 
isomers or deuterated internal standards.  HPLC-MS-MS, on the other hand, can perform 
such actions by using different retention times and ion selection pathways.  Seeding 
immunoassay wells manually does allow some versatility and control, but can be time 
consuming and requires experience.  Finally, the possibility of cross-reaction with biological 
components is an important consideration. 
 It is important to mention that the detection limit for the HPLC-MS-MS method used 
here was relatively high (8.813 ng/mL).  This limit would translate into levels normally found 
in human urine samples.  The immunoassay method required a 1:300 dilution of the spiked 
samples, reflecting the much greater sensitivity of the immunoassay method.  Such a 
difference reflects a weakness in the HPLC-MS-MS method used, indicating the need for 
further optimization.  It is apparent that immunoassay methods are in fact very sensitive.  It is 
suggested that the detection limit assay used in this exercise for HPLC-MS-MS is likely an 
overestimate compared to other methods, such as measuring the baseline noise. 
Analysis of 8-iso-PGF2α in urine using HPLC-MS with and without standards has shown 
that other metabolites exist – such as F2-isoprostane classes IV, V, and VI – that have very 
similar properties to 8-iso-PGF2α (Liang et al., 2003).  Tandem mass spectrometry removes this 
source of potential error by selecting further among the compounds with parent ions at 353 
m/z and fragmented ions at 193 m/z.  HPLC-MS-MS methods are still exposed to the risk of 
detecting diastereomers and other F2-isoprostanes with identical fragmentation pathways, 
which would need to be explored in further studies.  Compared to the supposed cross-
reactivities in EIA methods, this risk is believed to be small.  Immunoassay methods, while 
showing discrimination against most isomers, may not have safeguards against cross-
reactivities with isomers or metabolites (Lawson & FitzGerald, 2002).  It has been postulated 
that 8-iso-PGF2α is produced in vivo in lower amounts when compared to iPF2α –VI 
(Adiyaman et al., 1998), among others.  High specificity of the antibody used in enzyme 
immunoassay is required in order to prevent such cross-reaction.  Studies comparing GC-MS 
to EIA assert that such cross-reaction is minimal with regards to isomers and metabolites 
(O’Sullivan et al., 1999).  Since cross-reactivity among the isomers of the F2-isoprostanes are 
supposedly around 1% according to recent enzyme immunoassay kits, structurally unrelated 
compounds in biological samples have shown a greater possibility for error (Schwedhelm & 
Boger, 2003).  As indicated in the results, many of the urine samples analyzed by EIA (Groups 
A and C, Table III) possessed recoveries over 100%.  This may be an indication of isomers or 
biological materials in the urine causing cross-reactivity.  Further testing is needed to explore 
the extent of EIA cross-reactivity.   
 Overall statistical comparisons, using the linear mixed model and Bonferroni post hoc 
comparisons, indicated a significant difference in recovery obtained when performing solid 
phase and liquid phase extractions as opposed to merely performing liquid phase extraction 
(P<0.001).  In addition, large standard deviations were evident in the spiked urine samples 
purified by liquid extractions only.  This pattern was noticeable for both enzyme 
immunoassay and HPLC-MS-MS, with average recoveries 52.7% and 23.9% lower than solid 
phase extraction methods, respectively.  Due to the good yield and low standard deviation 
found in unpurified urine with EIA, the explanation could not lie in the necessity of higher 
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levels of purification.  It was hypothesized that the liquid phase extraction may have taken 
cell material and hydrophobic proteins from the urine matrix; material that solid phase 
extraction could remove.  During storage this material would precipitate and form insoluble 
complexes, trapping some 8-iso-PGF2α.  Indeed, observance of the vials kept in cold storage 
before analysis revealed that brown precipitated matter was glued to the bottom.  This matter 
seemed insoluble in the ethyl acetate and acetonitrile used for resuspension procedures for 
enzyme immunoassay and HPLC-MS-MS, respectively.  In further support of this theory, 
vials containing urine purified with solid phase extraction did not contain insoluble, 
precipitated, brown material.  Unpurified urine used in the EIA technique did not have this 
problem, as the 8-iso-PGF2α standard was added a few hours before testing.   
 Water and Urine samples spiked with 8-iso-PGF2α standard and analyzed by both EIA 
and HPLC-MS-MS gave unusual recoveries.  EIA analysis showed a better recovery for urine 
samples, while HPLC-MS-MS analysis had a better recovery for spiked water samples. These 
results, at first, seem inconsistent with previous findings.  Urine samples would theoretically 
be slightly higher in 8-iso-PGF2α concentration, as urine naturally possesses isoprostanes.  
However, levels found in urine are typically within 0.3-2.5 ng/mL, giving a difference in 
recovery of around 0.5-3.5%.  This deviation was largely surpassed, as urine samples 
determined by EIA possessed a 17% greater recovery compared to water samples.  This 
difference could be explained by possible cross-reactivity among different isomers and 
biological components, as mentioned earlier.  HPLC-MS-MS analysis showed that urine 
samples had a 55% lower recovery than spiked water samples.  Standard in urine samples, 
even though despite full sample preparation could have been trapped in precipitated matter 
during resolubilization, as explained above, even though this was visually not observed.  
Although it was suggested that solid phase extraction avoids precipitate problems, there may 
still be a probability that biological urine components can remain to bind the analyte.  More 
research is needed in order to reach a viable conclusion on these matrix effects.  However, the 
use of an internal standard would circumvent such problems by accounting for losses during 
all purification steps. 
 Another important observation from the water and urine sample simultaneous 
analysis was the low recovery found for spiked urine samples by Immunoassay compared to 
earlier trials (Group E against Group A in Table III).  This finding may indicate that there is 
noticeable uncertainty in the expected recoveries of immunoassay samples due to the nature 
of the physical components of the kits.  Also, there may be variation in the separation abilities 
of the solid phase extraction columns.  However, since the corresponding urine samples 
measured by HPLC-MS-MS (Group E in Table III) also had unexpected low recoveries, there 
is no justification in labeling immunoassay as less precise than HPLC-MS-MS.  Previous 
studies have found that immunoassay techniques possess significant variance between assays 
of the same standard when compared to GC-MS-MS (Il’Yasova et al., 2004).  Overall 
statistical analysis on the samples has shown that water and urine matrices do not yield 
similar results when processed simultaneously (P<0.001).  Urine possesses unique properties 
that have an effect on analysis, possibly linked to biological interference (constructive or 
inhibitive) or due to natural isomer concentrations.  Another possibility is that components of 
urine entrap compounds during frozen storage, preventing analysis of all standard present.  
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Regardless, larger scale studies are required comparing HPLC-MS-MS to Immunoassay 
techniques so that further conclusions on precision can be reached. 
 Deuterated standards were found to have similar recoveries as non-deuterated 8-iso-
PGF2α standards.  Analysis of the deuterated 8-iso-PGF2α standards by HPLC-MS-MS resulted 
in an average recovery of 86.02 +/- 5.69%.  Thus, approximately 14% of the recovery is lost 
due to the full purification methods.  This assumes that there was no exchange of deuterons 
and protons during the purification and analysis procedures.   Also, since the mean recovery 
for standards by HPLC-MS-MS (Group A in Table III) was 77.95 +/- 7.67%, there is a close 
resemblance between recoveries of deuterated and normal standards.  Comparison indicates 
that there is no significant difference between D4-8-iso-PGF2α and 8-iso-PGF2α analytes using 
this method (P=0.254). Such relatively high recovery indicated that very little of the 
isoprostane standard was lost during full purification procedures. Therefore, deuterated 
standards seem to be a valuable tool to correct for varying sample recovery. These deuterated 
standards can be taken to reveal the true amount of recovery using the full processing method 
followed by HPLC-MS-MS.       
Conclusion 
 In short, analysis of spiked urine samples by immunoassay and HPLC-MS-MS 
revealed that there is no significant difference in the recoveries obtained, however, a 
tendency for higher values obtained through immunoassay analysis was observed.  HPLC-
MS-MS offers good precision and analysis, given that enough time is spent to optimize the 
instrument conditions to its full potential and especially when including internal standards.  
Deuterated standards have shown to be a valuable tool for this purpose.  EIA methods do not 
require sophisticated instrumentation, but the precision can not be improved beyond its 
existing parameters. Liquid and solid phase extractions are a necessity for the HPLC-MS-MS 
analysis, while unpurified urine samples seem to yield good recoveries by immunoassay.  
Urine, as a matrix, seemingly can influence results in both ways.  Urine may create higher 
recoveries in immunoassay methods due to cross-reactivity, while precipitation and 
entrapment of the analyte seems a more predominant factor for HPLC-MS-MS assays.  
Ultimately, the decision between using HPLC-MS-MS and immunoassay would have to be 
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